Targeted Gut Microbiota Modulation Enhances Levodopa Bioavailability and Motor Recovery in MPTP Parkinson’s Disease Models
International Journal of Molecular Sciences · 30.05.2025 · 26 (11) · 5282
DOI: 10.3390/ijms26115282 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 30.05.2025. Verfasst von Penghui Ai und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology and Institute of Neurology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China. Hauptthemen laut MEDLINE: Gastrointestinal Microbiome, Levodopa, Parkinson Disease. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 54 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, National Key R&D Program of China, Shanghai Rising-Star Program.
Abstract (Originalsprache)
Emerging evidence highlights the gut microbiota as a pivotal determinant of pharmacological efficacy. While Enterococcus faecalis (E. faecalis)-derived tyrosine decarboxylases (tyrDCs) are known to decarboxylate levodopa (L-dopa), compromising systemic bioavailability, the causal mechanisms underlying microbiota-mediated pharmacodynamic variability remain unresolved. In our study, we employed antibiotic-induced microbiota depletion and fecal microbiota transplantation (FMT) to interrogate microbiota-L-dopa interactions in MPTP-induced Parkinson’s disease (PD) mice. The study demonstrated that antibiotic-mediated microbiota depletion enhances L-dopa bioavailability and striatal dopamine (DA) level, correlating with improved motor function. To dissect clinical heterogeneity in the L-dopa response, PD patients were stratified into moderate responders and good responders following standardized L-dopa challenges. In vitro bioconversion assays revealed greater L-dopa-to-DA conversion in fecal samples from moderate responders versus good responders. FMT experiments confirmed mice receiving good-responder microbiota exhibited enhanced L-dopa bioavailability, higher striatal DA concentrations, and a heightened therapeutic effect of L-dopa relative to moderate-responder recipients. Collectively, our study provided evidence that the gut microbiota directly modulates L-dopa metabolism and microbial composition determines interindividual therapeutic heterogeneity. Targeted microbial modulation—through precision antibiotics or donor-matched FMT—is a viable strategy to optimize PD pharmacotherapy, supporting the potential for microbiota-targeted adjuvant therapies in PD management.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurology and Institute of Neurology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China.
- Department of Geriatrics, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China.
ORCID-Profile: Yuan Yuan, Chengjun Mo, Xiaodong Yang
Förderung
- National Natural Science Foundation of China
- National Key R&D Program of China
- Shanghai Rising-Star Program
- National Key R&D Program of China
- Shanghai Sailing Program
Zitieren
APA
Ai, P., Xu, S., Yuan, Y., Xu, Z., He, X., Mo, C., Zhang, Y., Yang, X., & Xiao, Q. (2025). Targeted Gut Microbiota Modulation Enhances Levodopa Bioavailability and Motor Recovery in MPTP Parkinson’s Disease Models. International Journal of Molecular Sciences, 26(11), 5282. https://doi.org/10.3390/ijms26115282
Vancouver
Ai P, Xu S, Yuan Y, Xu Z, He X, Mo C, et al. Targeted Gut Microbiota Modulation Enhances Levodopa Bioavailability and Motor Recovery in MPTP Parkinson’s Disease Models. International Journal of Molecular Sciences. 2025;26(11):5282. doi:10.3390/ijms26115282
BibTeX
@article{Ai2025,
author = {Ai, Penghui and Xu, Shaoqing and Yuan, Yuan and Xu, Ziqi and He, Xiaoqin and Mo, Chengjun and Zhang, Yi and Yang, Xiaodong and Xiao, Qin},
title = {Targeted Gut Microbiota Modulation Enhances Levodopa Bioavailability and Motor Recovery in MPTP Parkinson’s Disease Models},
journal = {International Journal of Molecular Sciences},
year = {2025},
volume = {26},
number = {11},
pages = {5282},
doi = {10.3390/ijms26115282}
}
EUVIMED